Aibotics Inc.
AIBT
Aibotics, Inc. promotes the study of psychedelics for the treatment of mental health issues and supports the creation of both natural and synthetic molecules for the development of appropriate treatments. Aibotics also intends to deploy technology from its parent company, Ehave, Inc., in the collection of research and clinical data to further the study of the effects of psyche…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$2M
▼ -19.9% YoY
Op. Margin
-84501.74%
ROIC
-95.54%
▲ +89.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$180K
▼ -76.9% YoY
Op. Cash Flow (TTM)
-$180K
▼ -76.9% YoY
Net Debt
$968K
Cash & Equiv.
$223K
Continue Research
Peers
Medicinal Chemicals & Botanical Products · Pick stocks to compare with AIBT
Aibotics (AIBT) in three numbers
Questions about Aibotics
Is Aibotics (AIBT) overvalued?
Aibotics trades at 0.16 times earnings. Intrinsiqq's fair value calculator has no opening value for AIBT, so weigh those multiples against the company's own history and the peers above. See how to tell if a stock is overvalued.
Is Aibotics a high-quality business?
Aibotics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 5 checks computed from SEC filings. Its best check is share count change at 6830.0%. The Quality tab shows every check against its target.
Does Aibotics (AIBT) pay a dividend?
No. Aibotics (AIBT) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 20 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in AIBT's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing AIBT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.